Biogen (BIIB) Total Non-Current Liabilities (2009 - 2026)

Biogen (BIIB) has reported Total Non-Current Liabilities for 18 consecutive years, with $10.0 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 2.51% year-over-year to $10.0 billion; the TTM figure through Mar 2026 stood at $10.0 billion (down 2.51% YoY), while the FY2025 annual figure was $10.4 billion, down 1.57% from the prior year.
• Total Non-Current Liabilities came in at $10.0 billion for Q1 2026 at Biogen, down from $10.4 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $13.0 billion in Q3 2023, with the low at $9.9 billion in Q1 2023.
• Average Total Non-Current Liabilities over 5 years is $10.7 billion, with a median of $10.4 billion recorded in 2025.
• The largest YoY upside for Total Non-Current Liabilities was 19.07% in 2023 against a maximum downside of 17.68% in 2023.
• Year by year, Total Non-Current Liabilities stood at $10.2 billion in 2022, then increased by 10.2% to $11.3 billion in 2023, then slipped by 5.89% to $10.6 billion in 2024, then decreased by 1.57% to $10.4 billion in 2025, then fell by 3.74% to $10.0 billion in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $10.0 billion, $10.4 billion, and $10.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.